Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
179.43
+6.62 (3.83%)
At close: Oct 15, 2025, 4:00 PM EDT
179.42
-0.01 (-0.01%)
After-hours: Oct 15, 2025, 4:15 PM EDT
Natera Revenue
Natera had revenue of $546.60M in the quarter ending June 30, 2025, with 32.24% growth. This brings the company's revenue in the last twelve months to $1.96B, up 44.38% year-over-year. In the year 2024, Natera had annual revenue of $1.70B with 56.75% growth.
Revenue (ttm)
$1.96B
Revenue Growth
+44.38%
P/S Ratio
11.58
Revenue / Employee
$442,997
Employees
4,434
Market Cap
24.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.70B | 614.34M | 56.75% |
| Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
| Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
| Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
| Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NTRA News
- 2 days ago - Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings - Business Wire
- 2 days ago - Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium - Business Wire
- 14 days ago - Enrollment Tops 1,600 in Natera's EXPAND Trial of Single Gene NIPT - Business Wire
- 15 days ago - Natera Announces Publication of Signatera™ Validation Study in Testicular Cancer - Business Wire
- 16 days ago - Signatera™ Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows - Business Wire
- 21 days ago - Natera, Inc. (NTRA) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Can Natera Stock Reach $500? - Forbes
- 5 weeks ago - Natera, Inc. (NTRA) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha